Olema Pharmaceuticals
OLMA
91 hedge funds and large institutions have $155M invested in Olema Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 34 reducing their positions, and 21 closing their positions.
5.23% less ownership
Funds ownership: 95.38% → 90.15% (-5.2%)
6% less funds holding
Funds holding: 97 → 91 (-6)
29% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 21
29% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 34
49% less call options, than puts
Call options by funds: $179K | Put options by funds: $351K
57% less capital invested
Capital invested by funds: $359M → $155M (-$204M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$14.7M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$3.1M |
| 3 |
BlackRock
New York
|
+$1.4M |
| 4 |
Renaissance Technologies
New York
|
+$1.36M |
| 5 |
Goldman Sachs
New York
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.07M |
| 2 |
VA
VR Adviser
New York
|
-$7.64M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.68M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.2M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$3.11M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
ProShare Advisors
Bethesda,
Maryland
| – | -$105K | -11,173 | Closed |
|
|
QT
102
Quantamental Technologies
White Plains,
New York
| – | -$96K | -10,295 | Closed |
|
|
MIM
103
MetLife Investment Management
Whippany,
New Jersey
| – | -$89.6K | -9,573 | Closed |
|
|
MLICM
104
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$67.8K | -7,243 | Closed |
|
105
US Bancorp
Minneapolis,
Minnesota
| – | -$29K | -3,106 | Closed |
|
|
PA
106
Parallel Advisors
San Francisco,
California
| – | -$6K | -689 | Closed |
|
|
S
107
SignatureFD
Atlanta,
Georgia
| – | -$6K | -680 | Closed |
|
108
UBS Group
Zurich,
Switzerland
| – | -$573 | -104 | -80% |
|
|
QCG
109
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$1K | -57 | Closed |
|
OLMA Hedge Fund Activity: Q1 2022 in Review
91 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q1 2022, worth a combined $155M — down 57% from $359M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of OLMA and 15 opened new positions — a net loss of 6 holders — while 34 trimmed existing stakes and 24 added.
The largest buyer was Fairmount Funds Management, opening a new position worth an estimated $14.7M. The largest seller was RA Capital Management, cutting an estimated $9.07M.
- 91 institutional investors held Olema Pharmaceuticals (OLMA) as of Q1 2022, down from 97 in Q4 2021.
- Funds reported $155M of Olema Pharmaceuticals stock for Q1 2022, down 57% quarter-over-quarter.
- 15 funds opened new Olema Pharmaceuticals positions in Q1 2022 and 21 closed out, a net change of -6 holders.
- The largest Olema Pharmaceuticals buyer in Q1 2022 was Fairmount Funds Management, an estimated $14.7M added.
- The largest Olema Pharmaceuticals seller in Q1 2022 was RA Capital Management, an estimated $9.07M sold.
Based on aggregated 13F filings for Q1 2022.